Cetuximab

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cancer of Colon

Conditions

Cancer of Colon

Trial Timeline

Oct 17, 2017 → Dec 31, 2021

NCT ID

NCT03524820

About Cetuximab

Cetuximab is a phase 2 stage product being developed by Merck for Cancer of Colon. The current trial status is terminated. This product is registered under clinical trial identifier NCT03524820. Target conditions include Cancer of Colon.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03524820	Phase 2	Terminated	Oct 17, 2017	Dec 31, 2021	Cancer of Colon
NCT01192087	Phase 1/2	UNKNOWN	Jun 1, 2012	Jul 1, 2017	Adenoid Cystic Carcinoma
NCT01450319	Phase 2	Completed	Dec 1, 2011	Dec 1, 2014	Colorectal Neoplasms
NCT01382407	Pre-clinical	Completed	Jul 1, 2011	Apr 1, 2017	Colorectal Cancer Metastatic
NCT01230476	Phase 2	Terminated	May 1, 2010	May 1, 2015	Nasopharyngeal Carcinoma
NCT01142869	Pre-clinical	Terminated	Dec 31, 2009	Aug 5, 2014	Carcinoma, Squamous Cell
NCT01134666	Pre-clinical	Terminated	Nov 30, 2009	Aug 5, 2014	Colorectal Neoplasms
NCT01075841	Pre-clinical	Withdrawn	Mar 1, 2009	—	Neoplasms, Squamous Cell
NCT00865098	Phase 2	Completed	Mar 1, 2009	Jun 1, 2010	Carcinoma of the Head and Neck
NCT00827671	Phase 2	Terminated	Mar 1, 2009	Mar 1, 2016	Resectable Esophageal Cancer
NCT01075828	Pre-clinical	Completed	Mar 1, 2009	Jul 1, 2014	Head and Neck Cancer
NCT01074333	Pre-clinical	Terminated	Sep 1, 2008	Jan 1, 2012	Colorectal Neoplasm
NCT00714649	Phase 1/2	Completed	Jul 1, 2008	May 1, 2011	Head and Neck Cancer
NCT00522886	Phase 1	Completed	Apr 1, 2007	—	Non-small Cell Lung Cancer
NCT00251381	Phase 2	UNKNOWN	Nov 1, 2005	Nov 1, 2009	Oropharyngeal Neoplasms

Competing Products

20 competing products in Cancer of Colon

See all competitors

Product	Company	Stage	Hype Score
E7389	Eisai	Phase 1	33
Veliparib	AbbVie	Phase 2	52
AK-105	Akeso	Phase 1	32
XL820	Exelixis	Phase 1	30
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	69
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	69
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	33
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	51
Biomarkers blood, urine and microbiota samples	Eli Lilly	Pre-clinical	23
gemcitabine + paclitaxel + bevacizumab	Eli Lilly	Phase 2	52
pemetrexed	Eli Lilly	Phase 2	52
LY3300054 + Prexasertib	Eli Lilly	Phase 1	33
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	30
Cetuximab + Oxaliplatin + Capecitabine	Eli Lilly	Phase 2	52
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	52
Gemcitabine + Adriamycine + Paclitaxel	Eli Lilly	Phase 2	52
Selpercatinib	Eli Lilly	Pre-clinical	23
Pemetrexed + Cisplatin + Placebo + Pemetrexed	Eli Lilly	Phase 3	77
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT	Nanobiotix	Phase 1/2	36
NBTXR3	Nanobiotix	Phase 1/2	36

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved